sun pharma (DeutscheBank) Concerns on promoter diversifying into power are unwarranted

Promoters investing into power; Concerns seem unwarranted - (a) Sun has a clear growth strategy; (b) Significant cash with promoters; (c) Ability to maintain arms length relationships
Date Rating Target Price Recommendation Price Broker house
3 May 2011 hold 430 465 DeutscheBank Report

No comments:

Post a Comment